152 related articles for article (PubMed ID: 24346678)
1. Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Oliveira GL; Almeida AM; Silva AL; Brandão CM; Andrade EI; Cherchiglia ML; Acurcio Fde A
Rev Saude Publica; 2013 Aug; 47(4):769-78; discussion 779. PubMed ID: 24346678
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
Almeida AM; Silva AL; Brandão CM; Cherchiglia ML; Andrade EI; Araújo de Oliveira GL; Carmo RA; Acurcio Fde A
Rev Saude Publica; 2012 Dec; 46(6):942-9. PubMed ID: 23503535
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
[TBL] [Abstract][Full Text] [Related]
5. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
Veenstra DL; Spackman DE; Di Bisceglie A; Kowdley KV; Gish RG
Aliment Pharmacol Ther; 2008 Jun; 27(12):1240-52. PubMed ID: 18373637
[TBL] [Abstract][Full Text] [Related]
6. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
Lui YY; Tsoi KK; Wong VW; Kao JH; Hou JL; Teo EK; Mohamed R; Piratvisuth T; Han KH; Mihm U; Wong GL; Chan HL
Antivir Ther; 2010; 15(2):145-55. PubMed ID: 20386069
[TBL] [Abstract][Full Text] [Related]
8. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
9. Should chronic hepatitis B be treated as early as possible?
Hulstaert F; Schwierz C; Nevens F; Thiry N; Gamil M; Colle I; Van de Sande S; Horsmans Y
Int J Technol Assess Health Care; 2013 Jan; 29(1):35-41. PubMed ID: 23298548
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
11. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
Buti M; Brosa M; Casado MA; Rueda M; Esteban R
J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
[TBL] [Abstract][Full Text] [Related]
14. [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
Larry L; Lu XZ; Alison T
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):431-6. PubMed ID: 17594808
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of treatments for chronic hepatitis B.
Wiens A; Lenzi L; Venson R; Pedroso ML; Correr CJ; Pontarolo R
Braz J Infect Dis; 2013; 17(4):418-26. PubMed ID: 23849851
[TBL] [Abstract][Full Text] [Related]
16. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
Saab S; Ham MY; Stone MA; Holt C; Tong M
Liver Transpl; 2009 Apr; 15(4):413-20. PubMed ID: 19326401
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
Wang G; Liu Y; Qiu P; Zhou SF; Xu L; Wen P; Wen J; Xiao X
Drug Des Devel Ther; 2015; 9():2839-46. PubMed ID: 26082614
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
Buti M; Casado MA; Calleja JL; Salmerón J; Aguilar J; Rueda M; Esteban R
Aliment Pharmacol Ther; 2006 Feb; 23(3):409-19. PubMed ID: 16423000
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
Wang GL; Liu Y; Qiu P; Zhou SF; Xu LF; Wen P; Wen JB; Xiao XZ
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):866-72. PubMed ID: 27010143
[TBL] [Abstract][Full Text] [Related]
20. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
